Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.1045168
Keywords
chronic GVHD; Tregs; CAR; NK cells; ILCs; MSCs; extracellular vesicles
Categories
Funding
- COST (European Cooperation in Science and Technology)
- [COST Action 17138 EUROGRAFT]
Ask authors/readers for more resources
This review discusses immunomodulatory approaches for the prevention and treatment of chronic graft-versus-host disease (cGVHD), including T cells, NK cells, ILCs, MSCs, and extracellular vesicles. Clinical studies and pre-clinical research results are presented.
Hematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory complications can occur, among which chronic graft-versus-host disease (cGVHD) can be life-threatening. A classical therapeutic approach to the prevention and treatment of cGVHD has been broad immunosuppression, but more recently adjuvant immunotherapies have been tested. This review summarizes and discusses immunomodulatory approaches with T cells, including chimeric antigen receptor (CAR) and regulatory T cells, with natural killer (NK) cells and innate lymphoid cells (ILCs), and finally with mesenchymal stromal cells (MSC) and extracellular vesicles thereof. Clinical studies and pre-clinical research results are presented likewise.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available